Home
Contact
Sitemap
Santen Worldwide
HOME
About Santen
News
Investor Relations
Products
Careers
News Releases
News Releases
2009
2008
2007
2006
2005
2004
2003
2002
2009
Jul 3, 2009
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Jun 24, 2009
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
May 12, 2009
Santen Announces Financial Results for the Year ended March 31, 2009
May 12, 2009
Notice on Board of Directors
May 12, 2009
Santen to Issue Stock Acquisition Rights to the Corporate Officers for the Purpose of Granting Stock Options
May 12, 2009
Santen to Issue Stock Acquisition Rights to the Directors for the Purpose of Granting Stock Options
Apr 15, 2009
Santen and Merck & Co., Inc Sign Licensing Agreement for Tafluprost, Treatment for Glaucoma and Ocular Hypertension
Mar 3, 2009
Santen to Launch Sante FX V Plus OTC Eye Drop
Mar 3, 2009
Santen Pharmaceutical Co., Ltd. (Santen) licenses development, manufacturing and marketing rights of its hydrophobic acrylic lens material to Bausch & Lomb Inc.(B&L)
Feb 5, 2009
Santen Announces Financial Result for the Third Quarter ended December 31, 2008
Back to top
Download Adobe® Reader® to view PDF files.
